Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart drug entresto under safety watch in kids

NCT ID NCT06659393

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 30 children aged 1 to 17 with chronic heart failure who are taking Entresto for the first time. Researchers will monitor for side effects like low blood pressure, high potassium, kidney problems, and dehydration over 52 weeks. The goal is to understand how safe the drug is in real-world use for kids.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PEDIATRIC CHRONIC HEART FAILURE

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Ōbu, Aichi-ken, 474 8710, Japan

  • Novartis Investigative Site

    RECRUITING

    Toyoake, Aichi-ken, 4701192, Japan

  • Novartis Investigative Site

    RECRUITING

    Kurume, Fukuoka, 830-0011, Japan

  • Novartis Investigative Site

    RECRUITING

    Kurume, Fukuoka, 830-8543, Japan

  • Novartis Investigative Site

    RECRUITING

    Sapporo, Hokkaido, 060-8648, Japan

  • Novartis Investigative Site

    RECRUITING

    Tsukuba, Ibaraki, 3058576, Japan

  • Novartis Investigative Site

    RECRUITING

    Kawasaki, Kanagawa, 2168511, Japan

  • Novartis Investigative Site

    RECRUITING

    Yokohama, Kanagawa-ku, 236-0004, Japan

  • Novartis Investigative Site

    RECRUITING

    Tsu, Mie-ken, 514-8507, Japan

  • Novartis Investigative Site

    RECRUITING

    Nagasaki, Nagasaki, 852-8501, Japan

  • Novartis Investigative Site

    RECRUITING

    Ōmura, Nagasaki, 856-8562, Japan

  • Novartis Investigative Site

    RECRUITING

    Hidaka, Saitama, 350-1298, Japan

  • Novartis Investigative Site

    RECRUITING

    Saitama, Saitama, 330-8777, Japan

  • Novartis Investigative Site

    RECRUITING

    Hamamatsu, Shizuoka, 430-8558, Japan

  • Novartis Investigative Site

    RECRUITING

    Bunkyo Ku, Tokyo, 113-8655, Japan

  • Novartis Investigative Site

    RECRUITING

    Bunkyo Ku, Tokyo, 1138431, Japan

  • Novartis Investigative Site

    RECRUITING

    Bunkyo-ku, Tokyo, 113-8603, Japan

  • Novartis Investigative Site

    RECRUITING

    Fuchū, Tokyo, 183-0003, Japan

  • Novartis Investigative Site

    RECRUITING

    Fuchū, Tokyo, 1838561, Japan

  • Novartis Investigative Site

    RECRUITING

    Ōta-ku, Tokyo, 143 8541, Japan

  • Novartis Investigative Site

    RECRUITING

    Setagaya-ku, Tokyo, 1578535, Japan

  • Novartis Investigative Site

    RECRUITING

    Shinagawa-ku, Tokyo, 1428666, Japan

  • Novartis Investigative Site

    RECRUITING

    Shinjuku Ku, Tokyo, 1628666, Japan

  • Novartis Investigative Site

    RECRUITING

    Toyama, Toyama, 9300194, Japan

  • Novartis Investigative Site

    RECRUITING

    Akita, 010-8543, Japan

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Fukuoka, 8128582, Japan

  • Novartis Investigative Site

    COMPLETED

    Kumamoto, 862-8505, Japan

  • Novartis Investigative Site

    RECRUITING

    Okayama, 7008558, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.